EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Long‐term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open‐label, follow‐up trial

Lieven Lagae iD, Kerstin Alexandra Klotz iD, András Fogarasi iD, Florin Floricel, Christoph Reichel iD, Jan-Peer Elshoff, Sofia Fleyshman, Harriet Kang iD

Epilepsia · 2023-11 · 64 (11) · 2934-2946

DOI: 10.1111/epi.17754 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Epilepsia, online erschienen am 05.09.2023. Verfasst von Lieven Lagae und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Development and Regeneration, Pediatric Neurology Section, University Hospitals Katholieke Universiteit Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was undertaken to evaluate the long‐term safety, tolerability, and efficacy of adjunctive brivaracetam (BRV) treatment in pediatric patients with epilepsy.

Methods

A phase 3, open‐label, multicenter, long‐term follow‐up trial (N01266; NCT01364597) was conducted on patients (aged 1 month to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsyChildChild, PreschoolFemaleHumansMaleDouble-Blind MethodDrug Therapy, CombinationFollow-Up StudiesPyrrolidinonesSeizuresTreatment OutcomeInfantAdolescent

Stichwörter der Autor:innen

adolescentsantiseizure medicationchildrenfocal seizures

Substanzen

AnticonvulsantsbrivaracetamPyrrolidinones

Autor:innen und Institutionen

  • Department of Development and Regeneration, Pediatric Neurology Section, University Hospitals Katholieke Universiteit Leuven, Leuven, Belgium.
  • Department of Neuropediatrics and Muscle Disorders, Medical Center, University of Freiburg, Freiburg, Germany.
  • Department of Neuropediatrics, Bethesda Children's Hospital, Budapest, Hungary.
  • UCB Pharma, Monheim am Rhein, Germany.
  • UCB Pharma, Morrisville, North Carolina, USA.
  • Department of Neurology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA.

ORCID-Profile: Lieven Lagae, Kerstin Alexandra Klotz, András Fogarasi, Christoph Reichel, Harriet Kang

Förderung

  • UCB Pharma

Zitieren

APA

Lagae, L., Klotz, K. A., Fogarasi, A., Floricel, F., Reichel, C., Elshoff, J. P., Fleyshman, S., & Kang, H. (2023). Long‐term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open‐label, follow‐up trial. Epilepsia, 64(11), 2934-2946. https://doi.org/10.1111/epi.17754

Vancouver

Lagae L, Klotz KA, Fogarasi A, Floricel F, Reichel C, Elshoff JP, et al. Long‐term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open‐label, follow‐up trial. Epilepsia. 2023;64(11):2934-2946. doi:10.1111/epi.17754

BibTeX
@article{Lagae2023,
  author = {Lagae, Lieven and Klotz, Kerstin Alexandra and Fogarasi, András and Floricel, Florin and Reichel, Christoph and Elshoff, Jan-Peer and Fleyshman, Sofia and Kang, Harriet},
  title = {Long‐term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open‐label, follow‐up trial},
  journal = {Epilepsia},
  year = {2023},
  volume = {64},
  number = {11},
  pages = {2934--2946},
  doi = {10.1111/epi.17754}
}
Kostenlos starten →